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In the present study, we report the characterization of a 212-amino-acid polypeptide encoded by a splicing variant of the
Marek’s disease virus Eco-Q gene (Meq). This protein, referred to as Meq-sp, contains the N-terminal 100 amino acids of
Meq, which include part of Meq’s DNA binding/dimerization domain, but lacks the transactivation domain of Meq. Thus,
Meq-sp was examined for its ability to bind to DNA and act as a transactivator. Results indicated that while Meq and Meq-
sp could both bind to the AP-1 binding site, the 110 C-terminal amino acid residues of Meq-sp lacked the ability to function
as a transactivator when fused to the GAL4 (1-147) DNA binding motif. To investigate whether Meq-sp can interact with
Meq or with c-jun, protein–protein and protein–DNA interactions in vitro were examined. Results showed that Meq-sp can
associate with both Meq and c-jun and bind to the AP-1 site with a higher affinity as a heterodimer with c-jun. These results
suggest that Meq-sp could compete with Meq for heterodimer formation with c-jun and dimer binding to DNA and possibly
act as a transdominant negative regulator of Meq activity in vivo. q 1996 Academic Press, Inc.
INTRODUCTION Meq-sp detected a 28-kDa protein as well as the Meq
protein in the cell lysates of MDV-infected cells (Peng et
Marek’s disease virus (MDV) is an oncogenic avian al., 1995). Notably, a Marek’s disease nuclear antigen
herpesvirus which causes a lymphoproliferative disease (MDNA) of 28 kDa was reported to be present in the
in its natural host, the chicken (Calnek, 1980; Calnek, nuclear extracts of MKT-1 cells, which specifically bound
1992). MDV is classified as a member of the alphaher- to the BamHI-A fragment of the MDV genome (Wen et
pesviruses and contains long and short unique se- al., 1988). Whether these proteins are the same remains
quences (UL and US , respectively) each flanked by inter- to be determined.
nal/terminal long (IRL/TRL) and internal/terminal short In a previous study, it was demonstrated that Meq
(IRS/TRS) repeat sequences, respectively (Cebrian et al., binds to an AP-1-like motif present in its promoter and
1982; Fukuchi et al., 1984). It has been speculated that functions as a potent transcriptional activator when fused
the candidate MDV oncogenes reside within the inverted to the yeast Saccharomyces cerevisiae GAL4 (1-147)
repeats flanking UL and US (Kung et al., 1995). Among DNA binding domain (Qian et al., 1995). The maximum
these genes, the MDV Eco-Q protein (Meq), which is transactivating activity of Meq was observed when the
abundantly expressed in tumor cells (Jones et al., 1992; sequence residing within amino acids 209–339 (see Fig.
Peng et al., 1995) and has a classical basic-leucine zip- 1), which contains at least one proline repeat (not
per (bZIP) motif shared by the jun/fos-AP1 family of cellu- shown), was fused to GAL4. To gain insight into the bio-
lar oncogenes (Curran and Franza, 1988), has been logical activity of Meq-sp, we examined in the present
shown to participate in the maintenance of transforma- study whether Meq-sp possesses any transactivating or
tion by MDV (Xie et al., 1996). DNA binding activities.
Previously, we isolated a cDNA clone from the MDV-
transformed lymphoblastoid cell line, MKT-1, which en- MATERIALS AND METHODS
coded a variant of the Meq protein (Meq-sp) (Peng et al.,
Cell culture1995). Meq-sp is composed of 212 amino acids, of which
the 100 N-terminal amino acids are shared with Meq, Chicken embryo fibroblasts (CEF) were prepared from
but the remaining 112 amino acids are not related to 9-day-old embryos as described (Fukuchi et al., 1984)
Meq (Fig. 1). A polyclonal antibody directed against a and maintained in minimum essential medium (MEM)
protein sequence within the N-terminus of both Meq and supplemented with 5% newborn calf serum, 10% tryptose
phosphate broth, and 2% chicken serum. CEF were in-
fected with the MDV nonpathogenic vaccine strain1 To whom correspondence and reprint requests should be ad-
CVI988 (Rispens et al., 1972) at a passage level greaterdressed at Johns Hopkins Univ. Oncology Center, 418 N. Bond Street,
Baltimore, MD 21231. Fax: (410) 955-0840. than 100. COS-1, an African green monkey kidney cell
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and the primer 5*-AGCGTCGACTCAAAGACAGATATG-3*
containing the SalI restriction site as the downstream
primer. The PCR product was then cloned into the pCRII
vector (Invitrogen, San Diego, CA) and sequenced to gen-
erate the plasmid pCR-Meq-sp. These plasmids were
then used for in vitro transcription/translation using the
T7-directed TNT system (Promega Corp., Madison, WI),
according to the manufacturer’s instructions. The plas-
mid containing chicken c-jun cDNA [pGEM-7zf(0)/cJ-3]
was obtained from Dr. P. Vogt (Scripps Research Insti-
tute, La Jolla, CA) and used for in vitro transcription/
translation employing T7 polymerase.
FIG. 1. Structure of Meq and Meq-sp. Schematic diagram showing
the Meq and Meq-sp structures. The amino acid sequences in the CAT assays, DNA transfections, and gel-shift assays
putative bZIP domains of Meq-sp and Meq are shown.
CEF were transfected with up to 10–20 mg of each
DNA using the calcium phosphate coprecipitation
line, was maintained in MEM containing 10% bovine method (Wigler et al., 1979). COS-1 cells were electropor-
serum. ated with a total of 20 mg DNA/3 1 106 cells using the
Gene Pulser apparatus (Bio-Rad Laboratories, Rich-Primers and constructs
mond, CA) according to Chu et al. (1987). Forty-eight to
72 hr after transfection, the cell lysates were preparedThe plasmid pSG424 (Sadowski and Ptashne, 1989),
obtained from Dr. M. Ptashne (Harvard University, Cam- for the determination of the chloramphenicol acetyltrans-
ferase (CAT) activity using a CAT assay kit provided bybridge, MA), was used for the construction and expres-
sion of GAL4 (1-147) fusion with Meq-sp (pGal-Meq-sp) the Promega Corp. Gel-shift assays were also performed
according to an assay kit manufactured by Promegaas follows: The primer set 5*-TACGGATCCCACTGGAGA-
GTCTC-3* and 5*-AGCGTCGACTCAAAGACAGATATG-3* Corp. Nuclear extracts were prepared using a method
described by Stein et al. (1989).was used to amplify a DNA sequence corresponding to
amino acids 102–212 of Meq-sp from a plasmid con-
taining the entire Meq-sp ORF (Peng et al., 1995) by PCR. Antibody production
The PCR product was then subcloned into the BamHI–
SalI site of pSG424 and sequenced. All PCRs were per- The DNA sequence corresponding to amino acids
102–212 of Meq-sp was amplified by PCR using theformed as described previously (Peng et al., 1995). The
plasmid pG5BCAT containing five GAL4 DNA binding primer set 5*-ATCACTGGAGAGTATC-3* and 5*-TCAAAG-
ACAGATATGGG-3* from the plasmid containing the en-sites and pBXGAL-II, which contains the DNA binding
domain as well as the activation domain region II of tire Meq-sp ORF. The PCR product was then cloned into
the SmaI site of pGEX-4T-3 vector (Pharmacia, Piscata-GAL4, were also obtained from Dr. M. Ptashne. The plas-
mid Gal-Meq, containing amino acids 129–339 of Meq way, NJ) in-frame with the glutathione S-transferase
gene. The isolation of the fusion protein and productionfused to the GAL4 (1-147) DNA binding motif (Qian et al.,
1995), was kindly provided by Dr. H. J. Kung (Case West- of a rabbit polyclonal antibody were performed as de-
scribed previously (Peng et al., 1995).ern Reserve University, Cleveland, OH). The plasmid con-
taining the entire Meq ORF (pBS-Meq) was constructed
as follows: the fragments Bst1107I–BamHI and BamHI – Co-immunoprecipitation experiments
ClaI, obtained from the MDV BamHI-I2 and BamHI-Q2
genomic fragments, respectively (Fukuchi et al., 1984), Equal volumes of in vitro translated (IVT)-derived pro-
teins labeled with [35S]methionine (1175 Ci/mmol, NEN,were cloned into the SmaI–ClaI site of the pBSKS(0) vec-
tor. For optimal expression, the 5* sequence of the Meq Boston, MA) were co-incubated at 307 for 30 min prior to
the addition of 400 ml of the NTT buffer (300 mM NaCl,ORF was changed to a favorable Kozak sequence (Kozak,
1989) by PCR using the primer set 5*-AAGATGGCTCAG- 50 mM Tris, pH 7.4, 0.1% Triton X-100) and further incu-
bated at room temperature for 30 min. The appropriateGAGCCAGAGCCGGGCGCTAT-3* and 5*-GTTCATTGG-
CCCTCTGCAGCT-3*. The PCR product was then di- antibodies coupled with protein A–agarose (Gibco-BRL,
Grand Island, NY) were then added for 30 min at roomgested with PstI, ligated with the PstI – SalI fragment
of pBS-Meq, recloned into the SmaI – SalI site of the temperature to immunoprecipitate the proteins. The im-
mune complexes were then washed extensively and sub-pBSKS(0) vector, and sequenced. The 5* sequences of
Meq-sp ORF were also modified using the same jected to SDS–PAGE on a 12.5% gel followed by autoradi-
ography.upstream primer used for the modification of Meq,
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al., 1995). In addition to Meq, this antibody detected a
28-kDa protein, presumably corresponding to Meq-sp.
To substantiate the nature of the latter protein, we raised
a rabbit polyclonal antibody against amino acids 102–
212 of Meq-sp. As shown in Fig. 3, this antibody detected
only a 28-kDa protein corresponding to Meq-sp in the
nuclear fraction of CEF infected with the vaccine strain,
CVI988.
Meq-sp and c-jun heterodimerize and bind to the
AP-1 site
Recently, Qian et al. (1995) demonstrated that the prod-
uct of the Meq gene could bind to an AP-1-like DNA motifFIG. 2. Responsiveness of the CAT reporter gene to transactivation
by Meq and Meq-sp. CEF (A) and COS-1 (B) cells were transfected present in the Meq promoter and that this activity resides
with a CAT reporter plasmid containing five GAL4 binding sites. Cells within the sequence encompassing amino acids 1–129
were also cotransfected with either a construct containing only the of Meq. The authors also showed that Meq dimerizes
DNA binding domain of GAL4 (pSG424), used as a negative control,
not only with itself but also with c-jun and that Meq/c-or a construct containing both the DNA binding and transactivation
jun heterodimers bind to the AP-1-like site with a higherdomain II of GAL4 (pBXGAL-II), used as a positive control. Experimental
samples included cells that were cotransfected with either the pGal– affinity. Since Meq-sp shares its N-terminal 100 amino
Meq or pGal–Meq-sp fusion constructs. acids with Meq (see Fig. 1), we asked whether it retains
the ability to dimerize with Meq or c-jun and bind to
the same DNA target site as that of Meq. As the targetRESULTS
sequence, we employed an oligonucleotide containing
Assessment of the transactivation potential the symmetrical core sequence, TGAGTCA (AP-1 site,
of Meq-sp obtained from Promega Corp.), in gel-shift assays.
Results from co-immunoprecipitation experiments us-The Meq protein of MDV consists of two distinct re-
ing the IVT-derived proteins (Fig. 4) indicated that whilegions, namely the DNA binding/dimerization domain fol-
the antibody directed against the C-terminal domain oflowed by a proline-rich regulatory domain (Fig. 1). Pre-
Meq-sp was able to immunoprecipitate Meq-sp (lanes 1viously, it was shown that the latter sequence en-
and 7), it did not immunoprecipitate Meq alone (lane 6),compassing amino acids 129–339 functioned as a trans-
activator, when fused to the GAL4 (1-147) DNA binding
domain (Qian et al., 1995). Since the 112 amino acid C-
terminal residues of Meq-sp are not related to Meq (Fig.
1), we asked whether this region could also exhibit any
transactivating potential.
The Meq-sp C-terminal domain, consisting of the
amino acids 102 to 212, was fused in-frame to the GAL4
(1-147) DNA binding domain to generate pGal-Meq-sp.
This construct was co-transfected with a reporter plas-
mid, pG5BCAT, containing five GAL4 binding sites, into
either CEF or COS-1 cells. As shown in Fig. 2, Gal-Meq,
a GAL4 fusion gene containing amino acids 129–339 of
Meq, was able to activate the CAT reporter gene as
expected. However, the increase in CAT activity was
higher in CEF cells (Fig. 2A) than in COS-1 cells (Fig.
2B). By contrast, the C-terminal 110 amino acids of Meq- FIG. 3. Immunodetection of Meq-sp in MDV-infected cells. Nuclear
(N) and cytoplasmic (C) fractions from CEF (lanes 1 and 2, readingsp did not show any significant transactivating activity
from right to left) or CEF infected with the CVI988 for 6 hr (lanes 3 and(Fig. 2), although the fusion protein was efficiently ex-
4, reading from right to left) and 24 hr (lanes 5 and 6, reading from rightpressed in both cell types (not shown).
to left) were subjected to SDS–PAGE on a 12.5% gel and transferred to
nitrocellulose. The membranes were incubated with a rabbit polyclonal
Immunodetection of Meq-sp in MDV-infected cells antiserum raised against the C-terminus of Meq-sp (see text) and anti-
gen–antibody complexes were detected by a colorimetric reaction asPreviously, we demonstrated that a polyclonal rabbit
described previously (Peng and Shirazi, 1996). The bands of higher
antibody raised against amino acids 27–137 of Meq de- molecular weight represent cellular proteins that cross-react with this
tected a 44-kDa protein corresponding to Meq in the total antiserum. The numbers on the left (in kDa) indicate the size of the
prestained molecular weight markers (Bio-Rad).cell lysates of CEF lytically infected with MDV (Peng et
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RNA (Fig. 5A, lane 1 and Fig. 5B, lane 2) exhibited some
AP-1 binding activity as also observed by others
(Rauscher et al., 1988).
DISCUSSION
The Meq protein of MDV encoded within the BamHI-
I2 and the adjacent BamHI-Q2 genomic fragments is
abundantly expressed in MDV-transformed lymphoblas-
toid cell lines (Jones et al., 1992, Peng et al., 1995). Since
structurally Meq resembles transcription factors with
strong oncogenic activity, its potential role in MDV-in-
duced oncogenicity has been investigated by several
groups. For example, a recent study demonstrated that
when RNA antisense to the Meq gene was stably ex-
pressed in MSB-1, an MDV-transformed lymphoblastoid
cell line, the transfected cells displayed a significant re-
duction in colony formation in soft agar (Xie et al., 1996).
These results suggest that Meq could be involved in the
FIG. 4. Interaction of Meq-sp with Meq or c-jun. Co-immunoprecipita- maintenance of transformation by MDV. In this context,
tion experiments with the IVT-derived proteins were performed as de-
scribed under Materials and Methods. Lanes 1 and 7 are Meq-sp plus
anti-Meq-sp antibody; lane 2 is Meq-sp plus anti-c-jun antibody (Santa
Cruz Biotechnology Inc., Santa Cruz, CA); lane 3 is c-jun plus anti-c-
jun antibody; lane 4 is Meq-sp, c-jun, and anti-c-jun antibody; lane 5
is Meq plus anti-Meq antibody; lane 6 is Meq plus anti-Meq-sp anti-
body; lane 8 is Meq-sp, Meq, and anti-Meq-sp antibody. The location
and size (in KDa) of the prestained markers are shown on the left.
as expected. However, this antibody immunoprecipitated
both Meq and Meq-sp (lane 8) when they were co-incu-
bated prior to the addition of the antibody, suggesting
that Meq and Meq-sp can associate with each other in
vitro. Similarly, anti c-jun antibody immunoprecipitated
both Meq-sp and c-jun when they were co-incubated
(lane 4), but it did not immunoprecipitate Meq-sp alone
(lane 2).
To demonstrate the binding activity of Meq-sp alone
or Meq-sp in association with Meq or c-jun to the AP-1
site, gel-shift assays using the IVT-derived proteins were
performed. When Meq-sp and c-jun were mixed to allow
formation of Meq-sp/c-jun complexes prior to the DNA
binding assay, an increase in the AP-1 binding activity
was observed (Fig. 5A, lane 3). However, Meq-sp alone
did not exhibit a significant binding activity (Fig. 5A, lane
2), even at high molar concentrations of the probe (not FIG. 5. Cooperation in DNA binding of c-jun with Meq or Meq-sp.
(A) c-jun (lane 4), Meq-sp (lane 2), c-jun plus Meq-sp (lane 3), Meqshown). Similarly, no significant binding activity was ob-
(lane 5), or Meq plus Meq-sp (lane 6) were synthesized in reticulocyteserved when Meq-sp and Meq were mixed (Fig. 5A, lane
lysates, incubated with the AP-1 oligonucleotide end-labeled with6), even though Meq-sp and Meq were shown to interact
[g-32P]ATP (6000 Ci/mmol, NEN), and used in gel-shift assays. In lane
with each other (Fig. 4, lane 8). To demonstrate the bind- 1, lysates were used in the absence of DNA/RNA. Lanes 7 and 9
ing specificity of Meq-sp/c-jun complexes, nonlabeled represent c-jun plus Meq-sp in the presence of nonlabeled AP-1 and
AP-2 probes, respectively (50:1 molar ratio of competitor/probe). LanesAP-1 (Fig. 5A, lane 7) and AP-2 (Fig. 5A, lane 9) oligonu-
8 and 10 represent Meq-sp plus Meq in the presence of nonlabeledcleotide probes were used as specific and nonspecific
AP-1 and AP-2 probes, respectively (50:1 molar ratio of competitor/competitors, respectively. An increase in binding activity
probe). (B) Meq (lane 5), c-jun (lane 3), or Meq plus c-jun (lane 4) were
was also observed when Meq and c-jun were preincu- incubated with end-labeled AP-1 probe as in A. Lane 1 represents the
bated (Fig. 5B, lane 4), as also shown by Qian et al. labeled AP-1 probe alone, while lane 2 represents lysates in the ab-
sence of DNA/RNA.(1995). The reticulocyte lysates in the absence of DNA/
AID VY 8254 / 6a25$$$142 10-31-96 23:48:34 vira AP: Virology
81GENE TRANSCRIPTION IN MDV INVERTED REPEATS
it is important to mention that we have recently reported first two leucine heptad repeats, followed by an addi-
tional heptad repeat absent in Meq (Fig. 1, also see Pengthe isolation of cDNA clones which represent leftward
transcripts that are antisense to the Meq gene, sug- et al., 1995). The last leucine heptad repeat in Meq-sp
does not contain any helix-breaking amino acids suchgesting that in vivo, Meq’s expression could be modu-
lated by these naturally occurring RNAs (Peng and Shir- as glycine or proline, but rather contains charged amino
acids; therefore, it could participate in the formation of aazi, 1996). In addition, recent studies demonstrated that
Meq can function as a potent transcriptional activator, coiled-coil structure (Fig. 1). Our results suggest that
within the bZIP domain of Meq-sp, three or fewer leucinepossessing both DNA binding/dimerization and trans-
activating functions (Qian et al., 1995). heptad repeats are involved in dimerization between
Meq-sp and c-jun. Whether such a structural requirementSince the activity of other transcription factors, includ-
ing Meq, can be modulated via protein–protein interac- also exists for dimerization between Meq and c-jun re-
mains to be determined. For c-jun and c-fos, it has beention with other transcriptional activators, we examined
the ability of the protein product encoded by a splicing shown that the dimer-forming regions extend beyond the
last leucine to the conserved histidine residue (Cohenvariant of Meq, Meq-sp, to interact with Meq and/or to
function as a transcriptional activator. Meq-sp contains and Curran, 1990). However, our results strongly suggest
that the last leucine heptad repeat in Meq is dispensablethe N-terminal 100 amino acids of Meq, including part
of its DNA/bZIP domain, but is missing 239 C-terminal for this activity.
At present, the nature of the interaction between Meq-amino acid residues of Meq (Fig. 1). The latter sequence
was reported to be involved in the transactivating activity sp and Meq in vivo and its relationship to MDV-induced
oncogenicity is not clear. Qian et al. (1995) demonstratedof Meq (Qian et al., 1995). The major new findings of the
present study are that in contrast to Meq, Meq-sp does that Meq/c-jun heterodimers bind to the AP-1-like motif
present in the Meq promoter with a higher affinity thannot act as a transactivator when fused to the GAL4 (1-
147) DNA binding domain (Fig. 2). However, like Meq, Meq homodimers. In addition, they showed that Meq and
c-jun synergistically transactivated a reporter plasmidMeq-sp can interact with c-jun in vitro (Fig. 4). Although
Meq-sp alone exhibited no obvious specific DNA binding containing this AP-1-like motif in vivo. Since Meq-sp is
able to heterodimerize with c-jun (Fig. 4), it is possibleactivity to the AP-1 recognition sequence compared to
c-jun alone, it could bind with a higher apparent affinity that in vivo, Meq-sp competes with Meq for dimer forma-
tion with c-jun and dimer binding to DNA. A relevantas a Meq-sp/c-jun heterodimer (Fig. 5A). Whether Meq-
sp is unable to bind to DNA as a homodimer or whether example is an alternatively spliced form of FosB, which,
although it retains the ability to form DNA binding hetero-Meq-sp stabilizes Meq-sp/c-jun complex binding to DNA,
as is the case for c-fos (Rauscher et al. 1988), however, dimers with Jun, serves as a naturally occurring dominant
negative regulator of Fos-Jun activity (Nakabeppu andremains to be determined. It is also noteworthy that al-
though Meq-sp interacts with Meq in vitro (Fig. 4), it does Nathans, 1991). However, future studies are required to
address this possibility.not bind to DNA with a higher affinity in association with
Meq (Fig. 5A). Three possibilities can be considered to
explain these findings. First, the interaction of Meq with ACKNOWLEDGMENTS
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